Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

N/AActive Not RecruitingNCT06154902

Bristol-Myers Squibb350 enrolled

Overview

The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.

Study Type

OBSERVATIONAL

Enrollment

350

Conditions

Multiple Myeloma

Interventions

Idecabtagene vicleucelDRUG

According to approved product label in France

Not treatedOTHER

Eligible for idecabtagene vicleucel treatment but not treated

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with RRMM registered in the DESCAR-T registry and eligible for treatment or treated with idecabtagene vicleucel Exclusion Criteria: * Not registered with the social security in France

Locations (1)

DESCAR-T Registry

Paris, France

Outcomes

Primary Outcomes

Overall survival

Time frame: 15 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.